Académique Documents
Professionnel Documents
Culture Documents
ON No. L73100a1200SP1O10147
Wash* : unswariphermitin
SUN PHARMA
ADVANCED RESEARCH
COMPANY LTD.
SPARC/Sec/SE/2016-17/032
BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai -400001.
The Board of Directors of the Company at their meeting held today from 11:30 am to 01:45 pm
took the following decision:
i. Took on record and duly approved the Un-audited financial results of the Company for the
quarter and six months ended 30th June, 2016 which are enclosed herewith along with the
Limited Review Report of the Auditors thereon as Annexure I.
v
Approved the 'Statement of Deviation(s) & Variation(s)' in the use of proceeds from the
objects stated in the Offer documents of the recently concluded Rights issue of the Company,
which was already reviewed by the Audit Committee in its meeting held earlier during the day.
A copy of the same is enclosed herewith as Annexure II.
iii. Annulled the forfeiture of 191 equity shares of the Company held by the following shareholder
on favorable consideration of the applications from him along with the amount which remained
unpaid on the aforesaid shares.
Name of the Shareholder
Thanking you,
Yours faithfully,
For Sun harma Advanced Research Company Ltd
Debas
Company Secretary.
End: as above
191 shares
Statement of Unaudited Financial Results for the Quarter and Six Months ended September 30, 2016
Particulars
3 Months ended
30.09.2016
30.06.2016 30.09.2015
Unaudited
Unaudited
Unaudited
T In Lakhs
Year ended
. 31.03.2016
Audited
6 Months ended
30.09.2016
30.09.2015
Unaudited
Unaudited
9,489
9,489
2148
2,148
4,312
4,312
11,637
11,637
8,656
8,656
16,128
16,128
927
2,241
3,960
211
1,037
8,376
1,113
404
1,517
43
1,474
422
2,037
2,314
196
966
5,955
(3,807)
299
(3,508)
133
(3,641)
624
1,362
2,747
189
1,169
8,091
(1,779)
21
(1,768)
16
(1,774)
1,349
4,278
6,274
407
2,023
14,331
(2,694)
, 703
(1,991)
176
(2,167)
920
2,727
4,902
371
1,696
10,818
(1,060)
42
(1,918)
21
(1,939)
1,887
5,660
11,954
758
2,946
23,205
(7,077)
294
(6,783)
216
(6,999)
'
1,474
2,469
(3,641)
2,469
(1,774)
2,367
(2,167)
2,469
(1,939)
2,367
OLT
(1.47)*
(0.75)*
(0.813)*
(0.82)*
(6,999)
2,367
623
(2.96)
T in La khs
Mat
31.03.2016
Audited
"
Mat
30.09.2016
Unaudited
Particulars
i
4
2,489
23,366
25,825
2,367
623
2,990
190
05
218
329
547
273
_
329
602
6
7,700
1,394
364
9,463
5,248
5,815
1,209
212
12,484
,j,835
16 266
7,148
2,589
128
9,883
7,083
2,404
120
9,607
1
2,418
18,703
4,475
355
25,972
916
1,275
4,409
59
6,659
35,835
16,266
The above results are as per the Regulation 33 of the SEB1 (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its
meeting held on October 28, 2016 after being reviewed by the Audit Committee end have been subjected to a limited review by the Statutory Auditors of the Company.
The Company has only one reportable business segment namely 'Pharmaceutical Research 8 Development'.
During the quarter, the Company has annuled forfeiture of 4351, equity shares, pursuant to request received from the- concerned shareholders along with the unpaid call money with interest.
Previous periods (year figures have been regrouped (rearranged, wherever necessary, to correspond to current period's presentation.
order of the Board
3
4
eitfr
For Identification
Deloitte Haskins & Sells LLP
Dilip S. Shanghvi
Chairman and Managing Director
Status of Utilisation of rights issue proceeds for the Half year ended September 30, 2016
Particulars
Amount of
funds
required as
per the Letter
of Offer
Amount
utilised till
30th
September
2016
? In Laths
19,474
5,272
253
25,000
r in Laths
2,471
4,434
153
7,058
r in Lakhs
Balance
unutilised
amount as on
30th
September
2016
Z in Laths
17,003
838
101
17,942
01)
Dilip S. Shanghvi
Chairman and Managing Director